Welcome to our dedicated page for Sohm news (Ticker: SHMN), a resource for investors and traders seeking the latest updates and insights on Sohm stock.
SOHM Inc. (SHMN) regularly issues news updates that highlight its activities as a pharmaceutical and biotechnology company specializing in generic drugs, gene-editing tools, health and wellness solutions, and biotechnology-driven cosmeceuticals. Many of its announcements focus on progress in gene editing technologies, particularly its proprietary ABBIE genome-engineering platform, as well as corporate developments and strategic initiatives.
Readers of this news feed can expect coverage of gene editing platform milestones, such as technical advances in ABBIE, including Cas9-guided integrase work and later developments using a dCas12a domain to modify cultured human cells. The company has reported the creation of specialized cellular tools, including an ovarian cancer cell line with GYS1 overexpression for drug discovery applications, and it uses news releases to describe the scientific and research implications of these efforts.
SOHM’s news also includes intellectual property and regulatory developments, such as the allowance of a divisional patent in South Korea for Cas9 retroviral integrase and recombinase systems, and commentary on evolving regulatory frameworks for genome-editing technologies. Corporate and strategic updates appear as well, including facility relocation to a commercialization site in Vista, California, leadership and board appointments, and stated goals to enter biotechnology-driven cosmeceuticals.
In addition, the company reports on enhancements to its digital presence, including a redesigned corporate website and plans for an e-commerce platform to support cosmeceuticals, nutraceuticals, and over-the-counter products. For investors, researchers, and industry observers, this news page offers a centralized view of SOHM’s public communications on its gene editing work, broader product directions, governance changes, and operational expansion.
SOHM, Inc. (OTC:SHMN) has successfully developed a genetically modified ovarian cancer cell line (SKOV3) that overexpresses the GYS1 gene using their proprietary ABBIE™ platform. This breakthrough provides a valuable tool for screening GYS1 inhibitors, as GYS1 is a crucial enzyme in cellular energy metabolism linked to cancer cell survival. The engineered cell line, SKOV3-GYS1+, offers a ready-to-use system for evaluating GYS1-targeted compounds, particularly relevant for aggressive cancers like ovarian, breast, and pancreatic malignancies.
The ABBIE™ platform enables high-specificity gene editing without viral vectors, and SOHM plans to expand its engineered cell line portfolio for metabolic and immuno-oncology targets throughout 2025.
SOHM Inc. (OTC:SHMN) has appointed Dr. Leonardo Mirandola as Advisory Board Member to advance its CAR-T cell projects toward clinical trials. Dr. Mirandola, a biopharma scientist with over a decade of experience in oncology and cell therapy, previously served as CSO and Interim COO at Kiromic Biopharma, where he developed therapies including an FDA Fast-Track-designated allogeneic gamma-delta T-cell therapy for Stage 4 non-small cell lung cancer.
SOHM is leveraging its proprietary gene editing platform, ABBIE, to enhance CAR-T cell therapy commercialization. ABBIE offers advantages over traditional viral-based or CRISPR systems, including cost-efficiency, reduced manufacturing complexity, and fewer regulatory hurdles. The company aims to improve production timelines, genetic payload fidelity, and therapeutic window accessibility.
SOHM Inc. (OTC:SHMN) has secured a European patent for its innovative ABBIE genome editing technology. The patent (No. 3,277,805) specifically covers CAS 9 retroviral integrase and CAS 9 recombinase systems for targeted DNA sequence incorporation into cell or organism genomes. This achievement follows a recent patent grant in South Korea, with the European patent set to be published in the Patent Office Bulletin on May 7, 2025.
According to COO David Aguilar, this technology has significant potential applications in targeted gene therapies, cell therapy development, genetic disorder treatments, and agricultural improvements. The patent grant strengthens SOHM's position in the biotechnology sector and demonstrates its commitment to innovative R&D.
SOHM Inc (OTC PINK:SHMN) has announced a significant licensing agreement with an undisclosed drug development partner for its ABBIE genome editing technology focused on CAR-T cell cancer therapies. The company is set to receive $6 million in funding for advancing joint research initiatives.
The collaboration centers on SOHM's proprietary ABBIE (A Binding-based Integrase Enzyme) integration system, which aims to enhance the safe and efficient production of autologous CAR-T cells. The partnership combines SOHM's integration system with microfluidic gene editing capabilities to develop new micro-dosed CAR-T cell therapies for cancer treatment.
According to COO David Aguilar, PhD, this collaboration will position SOHM and its partners as leaders in microfluidic-based gene editing technology, potentially revolutionizing treatments for cancer and other diseases.
SOHM Inc. (OTC PINK:SHMN) has received a Notice of Allowance/Approval from the South Korea Patent Office for its innovative ABBIE gene editing technology. The patent covers the utilization of CAS 9 RETROVIRAL INTEGRASE and CAS 9 RECOMBINASE SYSTEMS for targeted DNA incorporation into cells or organisms.
This milestone expands SOHM's intellectual property portfolio in a key market, supporting licensing opportunities for novel cell therapies, agriculture, and biofuel applications. The company aims to strengthen its position in the global gene editing and cell therapy market, currently valued at $7.96 billion and $4.74 billion respectively in 2023.
The technology is expected to advance the development of new cell therapies for cancer and congenital diseases, while also supporting biofuel development and crop engineering.
SOHM Inc. (OTC PINK:SHMN) has announced significant developments in its biotechnology operations. The company is expanding its ABBIE genome editing and cell engineering program at their Carlsbad facility and UACI labs to support growing Next-Generation Sequencing (NGS) validation requirements.
The strategic expansion aims to meet increasing demands for engineered mouse models and cell lines important for drug development, gene therapy, and immunotherapy. The company is also enhancing its AI-enabled ABBIE platform for next-generation gene editing applications.
Additionally, SOHM will present a poster titled 'ABBIE Gene Editing: A Breakthrough in Precise, Replicable, and Traceable Genomic Integration' at the American Society of Gene and Cell Therapy Conference, scheduled for May 13-17 in New Orleans, LA.
SOHM Inc. (OTC PINK:SHMN) has announced the formation of a dedicated AI team to enhance its ABBIE (A Binding-based Integrase Enzyme) system and develop novel guide RNAs and RNA guided Integrase fusion proteins. The initiative aims to revolutionize genome editing and cell engineering technologies.
The AI team will utilize machine learning algorithms to optimize guide RNAs and Integrase-dCas fusion proteins design, improving the specificity, efficiency, and versatility of genome editing applications. The company plans to develop next-generation genome editing systems and create engineered cells producing custom exosomes with pharmaceutical properties.
According to COO Dr. David Aguilar, these custom exosomes will serve as targeted delivery vehicles for therapeutic agents, with applications in cancer therapy, regenerative medicine, and immunotherapy. The company aims to design exosomes that can efficiently transport drugs, genes, or RNA molecules to specific tissues.
SOHM Inc (OTC PINK:SHMN) has announced significant developments in their ABBIE Technology, revealing a strategic pivot in their business model. The company is transitioning from selling ABBIE kits for independent use to establishing a licensing model, leveraging their global Intellectual Property portfolio.
The company's breakthrough findings indicate that ABBIE technology features unique traceability capabilities absent in competing technologies, potentially streamlining FDA approval processes and enhancing therapy safety. SOHM is currently in technical diligence discussions with both small innovators and major pharmaceutical companies, focusing on applications in CAR-T therapy, cancer drug development, and gene therapy.
The company plans to publish these findings in Q2 2025 and will organize platform seminars to showcase the technology's potential in revolutionizing cancer treatment.
SOHM Inc. (OTC PINK:SHMN) has appointed Dr. Wei Zhu as Senior Marketing and Sales Consultant for its biotech ABBIE division. Dr. Zhu brings over 20 years of experience in Molecular and Cellular Biology, Biochemistry, Immunology, Signal Transduction, Cancer Biology, and Developmental Biology. Her expertise includes advanced Bioinformatics, Sequence-based Genomics Research, Histology, and animal model work. The appointment is effective immediately, and she will contribute to the company's marketing and sales efforts in pharmaceutical, cosmeceutical, and nutraceutical products.
SOHM Inc (OTC PINK:SHMN) has received a patent allowance from Japan's Patent Office for its ABBIE Genome Editing technology. The patent (No. 2023-121860) protects SOHM's innovative SAGE (SOHM-ABBIE Genome Editing) products and services, which enable precise DNA alterations without causing double-stranded breaks. This technology advancement positions SOHM competitively in the global Cell Therapy market, valued at $4.5 Billion in 2023 and projected to reach $97 Billion by 2033. The company plans to expand its presence in Japan, Korea, China, EU, and other global markets through product sales, services, and strategic partnerships.
FAQ
What is the current stock price of Sohm (SHMN)?
What is the market cap of Sohm (SHMN)?
